Tumor-associated antigen-derived epitope

A **tumor-associated antigen-derived epitope** refers to a short peptide fragment processed from a protein specifically or preferentially expressed by tumor cells (tumor-associated antigens), which is then presented on the cell surface in the context of a major histocompatibility complex (MHC) molecule. These epitopes serve as recognition elements for **T cell receptors (TCRs)** and can elicit immune responses—primarily from cytotoxic T lymphocytes—against tumor cells. Tumor-associated antigens may include mutated (neoantigen), viral, germline/cancer-testis, differentiation, or overexpressed self-antigens[1][3]. Peptide epitopes from these sources are essential for the development of cancer vaccines and immunotherapies[2][3]. The term "tumor-associated antigen-derived epitope" is a broad, generic descriptor rather than a specific molecular entity—it should be replaced by more precise antigen/epitope names (e.g., "Melanoma antigen recognized by T cells 1-derived epitope (MART-1-derived epitope)", "NY-ESO-1-derived epitope", "gp100-derived epitope")[2][3].

Other names

Tumor antigen-derived epitopeCancer-associated antigen epitopeTumor antigen epitope

Activation of tumor-specific cytotoxic T lymphocytes via MHC–peptide recognition Induction of anti-tumor immune response